<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964792</url>
  </required_header>
  <id_info>
    <org_study_id>P170006J</org_study_id>
    <nct_id>NCT03964792</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)</brief_title>
  <acronym>DREPAGLOBE</acronym>
  <official_title>A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients With Sickle Cell Disease (SCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the&#xD;
      Sickle Cell disease by Transplantation of an Autologous CD34+ enriched cell fraction that&#xD;
      contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the βAS3&#xD;
      globin gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients with Sickle Cell&#xD;
      Disease (SCD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">November 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of transplant related mortality</measure>
    <time_frame>up to 100 days post treatment</time_frame>
    <description>To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of the need for rescue autologous bone marrow transplant</measure>
    <time_frame>up to 100 days post treatment</time_frame>
    <description>To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of AEs post transplant transplant</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>Based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of vector-derived Replication competent lentivirus (RCL)</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically detectable malignancy and/or abnormal clonal dominance assessed as related to study treatment</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the procedure safety.It will be evaluated by vector insertion site analysis (VISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of neutrophil</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of platelet</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the efficacy. It will be quantified by High performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage HbAS3</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the efficacy. It will be quantified by High performance liquid chromatography It will be quantified by High performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the long -term safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of RCL (Replication competent lentivirus)</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>To evaluate the long -term safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of clinically detectable malignancy or abnormal clonal dominance assessed as related to study treatment</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>To evaluate the long -term safety. It will be evaluated by vector insertion site analysis (VISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression through percentage of anti-sickling Hb</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>To evaluate the long -term efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>DREPAGLOBE drug product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DREPAGLOBE drug product</intervention_name>
    <description>Each patient will receive a single IV infusion of DREPAGLOBE drug product</description>
    <arm_group_label>DREPAGLOBE drug product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Age 12-20 years&#xD;
&#xD;
          -  Diagnosis of HbSS or S-beta zero thalassemia by Hb electrophoresis or genetic&#xD;
             analysis.&#xD;
&#xD;
          -  Clinical history or ongoing evidence of severe sickle cell anemia with one OR more of&#xD;
             the following clinical complications demonstrating disease severity:&#xD;
&#xD;
               -  At least 3 vaso occlusive crises requiring hospitalization, under hydroxyurea or&#xD;
                  transfusion, within 2 years prior to enrollment&#xD;
&#xD;
               -  One severe acute chest syndrome (ACS) hospitalized in intensive care unit&#xD;
&#xD;
               -  At least 2 episodes of ACS within the prior 3 years), including one under HU.&#xD;
&#xD;
               -  Acute priapism (at least 2 episodes &gt; 3h in the preceding year or in the year&#xD;
                  prior to the start of a regular transfusion program), OR stuttering priapism ≥ 1&#xD;
                  by week under sickle cell treatment (HU, transfusion or phlebotomy).&#xD;
&#xD;
               -  Cerebral vasculopathy confirmed by MRA (magnetic resonance angiography) without&#xD;
                  Moya-moya&#xD;
&#xD;
               -  Presence of sickle cell cardiomyopathy documented by Doppler echocardiography&#xD;
                  (left ventricular ejection fraction (LVEF) &lt;55% AND tricuspid regurgitation&#xD;
                  velocity &gt;2.5m/s on cardiac echocardiograph),&#xD;
&#xD;
               -  Tricuspid regurgitation velocity &gt;2.8m/s on cardiac echocardiograph without&#xD;
                  pulmonary hypertension confirmed by right heart catheterization (mPAP&lt;25mmHg)&#xD;
&#xD;
          -  Failed hydroxyurea (HU) therapy, were unable to tolerate HU therapy, or, if 18 years&#xD;
             of age or older, have actively made the choice to not take the recommended daily HU&#xD;
             regimen. Inadequate clinical response to HU, defined as any one of the following&#xD;
             outcomes, while on HU for at least 3 months: 2 or more acute sickle pain crises&#xD;
             requiring hospitalization, no rise in Hb &gt;1.5 gm/dl from pre-HU baseline or requires&#xD;
             transfusion to maintain Hb &gt; 6.0 gm/dL, had an episode of ACS despite adequate&#xD;
             supportive care measures.&#xD;
&#xD;
          -  Karnovsky/Lansky performance score ≥ 60%&#xD;
&#xD;
          -  Sexually active patients must be willing to use an acceptable method of double-barrier&#xD;
             contraception for at least 12 months post-infusion (beyond 12 months at the discretion&#xD;
             of the investigator)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chromosomal (karyotyping) or molecular anomalies (detected by NGS) ( ie 7 chromosomal&#xD;
             monosomy)&#xD;
&#xD;
          -  Existence of a matched sibling donor&#xD;
&#xD;
          -  Patients who have started new treatment for SCD within 6months of enrollment&#xD;
&#xD;
          -  Hematologic evaluation: Leukopenia (WBC &lt; 3000 µL) ( en cours) or neutropenia (ANC &lt;&#xD;
             1000 µL) or thrombocytopenia (platelet count &lt; 100,000 µL) (not due to an&#xD;
             erythropheresis procedure)&#xD;
&#xD;
          -  PT/INR or PTT &gt; 1.5 times upper limit of normal (ULN) or clinically significant&#xD;
             bleeding disorder&#xD;
&#xD;
          -  Evaluations within 6 months prior to screening visit:&#xD;
&#xD;
          -  ALT or AST &gt; 3 times ULN&#xD;
&#xD;
          -  Liver Cirrhosis suspicion on echography, CT scan or MRI AND confirmed by histology&#xD;
&#xD;
          -  Cardiac evaluation: LVEF &lt; 40% by cardiac echocardiogram or by MUGA scan&#xD;
&#xD;
          -  Stroke with significant CNS sequelae i.e., Rankin &gt; 2&#xD;
&#xD;
          -  Lung interstitial infiltrate AND Forced Vital Capacity less than 70% AND DLCO less&#xD;
             than 60% at steady state&#xD;
&#xD;
          -  Confirmed pulmonary hypertension defined by a right heart catheterization&#xD;
             (PAPm&gt;25mmHg). Right heart catheterization is required if tricuspid regurgitation&#xD;
             velocity &gt;2.8m/s on cardiac echocardiograph OR &gt;2.5m/s with an abnormal Brain&#xD;
             Natriuretic Peptide dosage or an important decrease in transcutaneous Hb O2 saturation&#xD;
             during the 6 minutes walk test.&#xD;
&#xD;
          -  Seropositivity for HIV (Human Immunodeficiency Virus), HCV (Hepatitis C Virus), HTLV-1&#xD;
             (Human T-Lymphotropic Virus), or active Hepatitis B Virus, or active infection by CMV&#xD;
             or parvovirus B19, based on positive blood PCR.&#xD;
&#xD;
          -  Pregnancy or breastfeeding in a postpartum female&#xD;
&#xD;
          -  Any current cancer or prior history of a malignant disease, with the exception of&#xD;
             curatively treated non-melanoma skin cancer&#xD;
&#xD;
          -  Immediate family member with an established or suspected Familial Cancer Syndrome&#xD;
&#xD;
          -  Diagnosis of significant psychiatric disorder of the subject that could seriously&#xD;
             impeded the ability to participate in the study&#xD;
&#xD;
          -  Patients who failed previous HSCT and are severely ill&#xD;
&#xD;
          -  Any clinically significant active infection&#xD;
&#xD;
          -  Participation in another clinical study with an investigational drug within 30 days of&#xD;
             screening&#xD;
&#xD;
          -  Any condition, based on perspective of the medical monitor and treating investigator,&#xD;
             which may lead to increased safety risk or inability to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo BARTULOCCI, MD &amp; PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of internal medicine, Henri-Mondor Hospital, Creteil, France.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina CAVAZZANA, MD &amp; PhD</last_name>
    <phone>+33 144495068</phone>
    <email>m.cavazzana@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE, Manager</last_name>
    <phone>+33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Biotherapy, Necker-Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina CAVAZZANA, MD &amp; PhD</last_name>
      <phone>+33 144495068</phone>
      <email>m.cavazzana@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

